Intellia Therapeutics has said it will reduce its headcount by 27% this year and shelve early-stage R&D programmes as it puts its resources behind two priority drug candidates. The specialist in ...

Intellia Therapeutics' stock is downgraded to HOLD due to market skepticism and lack of near-term catalysts despite promising Phase 3 trials for HAE and ATTR. NTLA-2002, Intellia's CRISPR/Cas9 ...

Intellia Therapeutics has a 12-month low of $8.30 and a 12-month high of $32.00. The firm has a market cap of $1.07 billion, a PE ratio of -1.90 and a beta of 1.97. Insider Transactions at ...

In this article, we are going to take a look at where Intellia Therapeutics, Inc. (NASDAQ:NTLA) stands against other small–cap stocks insiders are selling recently. Why are some investors ...

Cambridge-based Intellia has its headquarters at 40 Erie Street, where it occupies around 65,000 square feet of office and lab space. Intellia Therapeutics Inc. is shaking up its Cambridge and ...

CAMBRIDGE, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...

CASE DETAILS: According to the complaint, defendants provided investors with material information concerning Intellia's Phase 1/2 study evaluating NTLA-3001 for the treatment of alpha-1 ...

Truist analyst Joon Lee lowered the firm’s price target on Intellia Therapeutics (NTLA) to $50 from $90 and keeps a Buy rating on the shares. Intellia’s restructuring should help extend the ...